PARP1 and cancer: All of these are poly (ADP-ribose) polymerase 1 inhibitors (PARPi) and their application has successfully been translated into therapy, mainly in combination with homologous recombination deficient (HRD) tumors, not only including BRCA mutations, but also the ones imitating BRCA-mutated cancers, called BRCA-associated or BRCAness.